rTMS in the Prevention and Treatment of Postoperative Executive Dysfunction
Launched by XUZHOU CENTRAL HOSPITAL · Oct 10, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a treatment called repetitive transcranial magnetic stimulation (rTMS) to see if it can help prevent and treat problems with thinking and memory that some patients may experience after heart valve surgery. Researchers believe that rTMS can improve brain function by helping to fix certain brain network problems and reducing inflammation that can affect how well people think after surgery. The goal is to find out if this treatment can make a difference for patients recovering from surgery.
To be eligible for this trial, participants must be between 45 and 75 years old and scheduled for heart valve replacement surgery. However, people with certain health conditions, such as severe brain injuries or organ failures, and those with specific mental health issues or substance abuse problems, cannot participate. If you join the study, you will receive rTMS treatment and may help researchers learn more about how to improve cognitive function after surgery. This trial is currently recruiting participants, so it’s a great opportunity for those who qualify to contribute to important medical research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Heart valve replacement.
- • 45 to 75 years old.
- Exclusion Criteria:
- • definite cerebral infarction.
- • failure and decompensation of vital organs
- • physical metal implants.
- • severe neuropsychiatric disorders.
- • less than 9 years of education.
- • alcohol abuse.
- • drug dependence.
About Xuzhou Central Hospital
Xuzhou Central Hospital is a leading medical institution located in Xuzhou, China, renowned for its commitment to advancing healthcare through innovative research and clinical excellence. As a comprehensive teaching hospital, it is equipped with state-of-the-art facilities and a multidisciplinary team of specialists dedicated to providing high-quality patient care and conducting clinical trials. The hospital actively engages in research initiatives aimed at enhancing treatment modalities and improving patient outcomes, positioning itself as a pivotal contributor to the medical community both nationally and internationally. With a focus on ethical practices and patient safety, Xuzhou Central Hospital strives to foster advancements in medical knowledge and therapeutic interventions through rigorous clinical investigation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Xuzhou, Jiangsu, China
Patients applied
Trial Officials
Yangzi Zhu, Doctor
Principal Investigator
Xuzhou Central Hospital
Liwei Wang, Doctor
Study Director
Xuzhou Central Hospital
Qi Yang, Doctor
Study Director
Beijing Chao Yang Hospital
Daqing Ma
Study Chair
Imperial College London, Chelsea and Westminster Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials